These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 37999101)

  • 1. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
    Duttagupta S; Hakozaki T; Routy B; Messaoudene M
    Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
    Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
    Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.
    Nyein AF; Bari S; Hogue S; Zhao Y; Maller B; Sha S; Gomez MF; Rollison DE; Robinson LA
    BMC Cancer; 2022 Jan; 22(1):101. PubMed ID: 35073876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
    Xin Y; Liu CG; Zang D; Chen J
    Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
    Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
    J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
    Derosa L; Hellmann MD; Spaziano M; Halpenny D; Fidelle M; Rizvi H; Long N; Plodkowski AJ; Arbour KC; Chaft JE; Rouche JA; Zitvogel L; Zalcman G; Albiges L; Escudier B; Routy B
    Ann Oncol; 2018 Jun; 29(6):1437-1444. PubMed ID: 29617710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.
    Nucera F; Ruggeri P; Spagnolo CC; Santarpia M; Ieni A; Monaco F; Tuccari G; Pioggia G; Gangemi S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
    Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
    Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
    Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
    Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
    Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
    Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
    Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
    J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad-spectrum antibiotics associated gut microbiome disturbance impairs T cell immunity and promotes lung cancer metastasis: a retrospective study.
    Xu K; Cai J; Xing J; Li X; Wu B; Zhu Z; Zhang Z
    BMC Cancer; 2022 Nov; 22(1):1182. PubMed ID: 36384523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
    Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
    Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the gut microbiota in tumor, immunity, and immunotherapy.
    Xie Y; Liu F
    Front Immunol; 2024; 15():1410928. PubMed ID: 38903520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and immunotherapy of renal cell carcinoma.
    Bibbò S; Porcari S; Del Vecchio LE; Severino A; Mullish BH; Ianiro G; Gasbarrini A; Cammarota G
    Hum Vaccin Immunother; 2023 Dec; 19(3):2268982. PubMed ID: 37955340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.